DOD Biotech Public Co., Ltd.

DOD Biotech Public Co., Ltd.

0.81
THB
0.00
(0.00%)
0.01EPS
314.55P/E
581.03MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.01
0.41
0.94
0.89
1.84
1.92
2.62
2.47
1.31
1.52
1.43
1.35
1.16
Basic EPS, GAAP
- -
0.11
0.31
0.34
0.84
0.21
0.34
0.12
-0.97
0.02
-0.35
0.13
- -
Free Cash Flow per Basic Share
- -
-0.11
0.14
0.1
0.07
-0.81
0.47
-0.09
-0.47
0.01
0.03
0.09
-0.21
Dividend per Share
- -
- -
0.1
0.39
0.72
0.44
0.35
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
0.32
0.74
0.87
2.88
2.97
2.95
3.12
2.16
2.35
2
2.13
2.04
Tangible Book Value per Share
- -
0.32
0.74
0.87
2.88
2.64
2.93
3.1
2.15
2.24
1.9
2.04
1.96
Basic Weighted Avg Shares
411
411
411
411
361
411
411
411
410
435
450
450
455
Sales/Revenue/Turnover
2
170
385
368
666
790
1,077
1,015
537
664
645
609
529
Operating Margin (%)
-23.97
27.85
34.24
37.57
46.3
10.92
33.12
30.61
-2.12
13.24
2.24
6.46
-0.1
Depreciation Expense
- -
2
4
8
22
54
77
67
65
73
61
43
45
Net Income, GAAP
- -
47
129
139
305
87
141
50
-398
7
-159
60
2
Effective Tax Rate (%)
- -
- -
2.17
- -
0.77
6.04
10.43
12.06
- -
30.49
32.89
- -
- -
Profit Margin (%)
-23.97
27.85
33.49
37.75
45.81
10.98
13.11
4.9
-74.16
1.08
-24.69
9.78
0.35
Working Capital
- -
100
142
61
318
151
205
367
-107
89
251
381
255
LT Debt
3
20
16
41
1
33
27
73
58
53
- -
57
51
Total Equity
-1
95
224
262
1,184
1,238
1,225
1,262
894
1,080
892
954
914
Return on Invested Capital (%)
- -
81.42
72.2
- -
40.67
6.2
20.76
16.65
- -
8.72
4.11
- -
- -
Return on Capital (%)
- -
81.42
72.18
- -
40.92
8.34
10.93
5.99
- -
0.99
-11.44
- -
- -
Return on Common Equity (%)
- -
- -
80.93
57.1
42.2
7.21
11.61
3.99
-36.75
0.74
-16.29
6.42
0.2

Capital Structure

THB

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
13
13
17
LT Borrowings
57
54
51
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
450
450
450
Market Capitalization
730
784
581

Working Capital

THB

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
497
386
387
Cash, Cash Equivalents & STI
290
114
110
Accounts Receivable, Net
53
58
72
Inventories
112
98
113
Total Current Liabilities
116
118
132
Payables & Accruals
83
76
89
ST Debt
13
13
17
Deferred Revenue
19
27
26

Growth Rates

THB

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
49.23%
-3.16%
6.94%
Free Cash Flow
-119.83%
118.97%
244.72%
Net Income, GAAP
-322.94%
-704.21%
-137.4%
Sales/Revenue/Turnover
22.08%
-7.54%
-5.64%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

THB

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
169
154
172
150
645
2025
171
151
145
142
609
2026
120
122
- -
- -
- -

Quarterly Earnings Per Share

THB

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
-0.38
0.02
0.01
-0.35
2025
0.06
0.02
0.02
0.03
0.13
2026
-0.05
- -
- -
- -
- -

Quarterly Dividends Per Share

THB

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Torlarp Chaiyachow
Full Time Employees
258
Sector
Health technology
Industry
Pharmaceuticals: other
Address
No. 111 Moo 2, Tha Chin Sub-district Samut Sakhon SS Thailand 74000
IPO Date
Jun 20, 2018
Business
DOD Biotech Public Company Limited manufactures and distributes nutritional supplements, dietary products, cosmetics, and health drinks in Thailand. The company offers dietary supplements for beauty and health in forms including capsules, gels, jellies, powders, shot drinks, soft gels, tablets, probiotics, gummies, and direct-to-mouth products; skincare solutions for clarifying, anti-aging, moisturizing, acne control, and dark spot reduction; body shaping supplements such as metabolic boosters, carbohydrate blockers, fat inhibitors, and appetite suppressants; health care items targeting brain function, bones and joints, excretory system, sleep, immunity, vitamins, blood sugar, vision, hair, and cardiovascular care; proteins including whey and plant-based options, power gels, and energy drinks; and body wellness products for men and women. It also provides advisory, trading, research and development, FDA and HALAL registration, and consulting services through segments encompassing supplementary business, cosmetic manufacturing, extraction manufacturing, and others. DOD Biotech Public Company Limited, founded in 2011 and headquartered at No. 111 Moo 2, Tha Chin Sub-district, Mueang Samut Sakhon District, Samut Sakhon, Thailand, operates primarily in the domestic market with subsidiaries including DOD Healthy Life Co., Ltd., DOD Sale Power Co., Ltd., Siam Herbal Tech Co., Ltd., A Metaverse Co., Ltd., and DOD Infinite Co., Ltd. In recent developments, the company restructured by ceasing operations of loss-making subsidiary Siam Herbal Tech Co., Ltd. to focus on core growth areas; invested in gummy production machinery with capacity up to 1 million pieces per month, upgraded warehouse processes with an automated Warehouse Management System, and enhanced research and development; expanded its customer base to doctors, pharmacists, aesthetic clinics, and cosmetics sectors for 60-70 monthly orders; and signed a memorandum of cooperation with the Thailand Institute of Scientific and Technological Research and Precision X Co., Ltd. to develop probiotic products for global markets.